Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Icecure Medical ( (ICCM) ) has shared an announcement.
On September 18, 2025, IceCure Medical announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office for its next-generation XSense™ Cryoprobes. This new technology, designed to improve cryoprobe extraction and reduce tissue trauma, enhances the company’s cryoablation platform, potentially lowering costs and improving patient experiences. The XSense™ system, which recently gained regulatory approval in the U.S. and Israel, positions IceCure Medical as a leader in minimally invasive tumor destruction, offering significant implications for stakeholders by expanding its market reach and enhancing its technological offerings.
The most recent analyst rating on (ICCM) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
Spark’s Take on ICCM Stock
According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral.
Icecure Medical’s overall stock score is driven by significant financial challenges, including declining revenues and ongoing losses, which weigh heavily on the score. Despite these issues, the company’s strong regulatory progress and clinical achievements, particularly with ProSense, provide a positive outlook. Technical indicators suggest some stability, but valuation concerns persist due to the negative P/E ratio and lack of dividend yield.
To see Spark’s full report on ICCM stock, click here.
More about Icecure Medical
IceCure Medical, listed on Nasdaq as ICCM, specializes in developing and marketing advanced cryoablation therapy systems that utilize liquid nitrogen to destroy tumors by freezing. The company’s primary focus areas include breast, kidney, bone, and lung cancer, offering a minimally invasive alternative to traditional surgical tumor removal. Their flagship ProSense® system is marketed globally, with approvals in the U.S., Europe, and Asia.
Average Trading Volume: 1,760,892
Technical Sentiment Signal: Sell
Current Market Cap: $70.07M
For a thorough assessment of ICCM stock, go to TipRanks’ Stock Analysis page.